Use of compassionatecase ATMP in preclinical data for clinical trial applications

The Lancet

Volumn 379, Issue 9834, 2012, Pages 2341-

  Lowdell, Mark W ^a   Birchall, Martin ^a   Thrasher, Adrian J ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED THERAPY MEDICINAL PRODUCT; HERBACEOUS AGENT; UNCLASSIFIED DRUG;

AUTHORITY; CLINICAL TRIAL (TOPIC); DRUG MANUFACTURE; DRUG SAFETY; EUROPE; HUMAN; LAW; LETTER; PERSONALIZED MEDICINE; PHYSICIAN; PRIORITY JOURNAL; RISK ASSESSMENT; SURGEON; ANIMAL; ANIMAL MODEL; BIOMEDICAL TECHNOLOGY ASSESSMENT; EMPATHY; EXPERIMENTAL THERAPY; METHODOLOGY;

ANIMALS; CLINICAL TRIALS AS TOPIC; EMPATHY; HUMANS; MODELS, ANIMAL; TECHNOLOGY ASSESSMENT, BIOMEDICAL; THERAPIES, INVESTIGATIONAL;

EID: 84862626037     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)61018-6     Document Type: Letter

References (1)

1. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase I trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355: 1018-28